Active, not recruiting
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
NCT06444880
- Conditions
- Epithelioid Sarcoma, Neoplasms, Neoplasms by Histologic Type, +4 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States